Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives Joan MinguetKatherine H. SmithPeter Bramlage Review Article 12 May 2015 Pages: 219 - 233
Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer Fadi S. FarhatMarwan G. GhosnJoseph G. Kattan Original Article 30 May 2015 Pages: 235 - 242
Pharmacokinetic drug–drug interaction assessment of peptibody trebananib in combination with chemotherapies Benjamin WuRebeca MelaraYu-Nien Sun Original Article 02 June 2015 Pages: 243 - 250
Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703 Kenichiro KudoKatsuyuki HottaKatsuyuki Kiura Original Article 03 June 2015 Pages: 251 - 256
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma Mi Na KimSimon Weonsang RoKwang-Hyub Han Original Article 03 June 2015 Pages: 257 - 267
Elemental diet moderates 5-fluorouracil-induced gastrointestinal mucositis through mucus barrier alteration Rei KawashimaFumitaka KawakamiTakafumi Ichikawa Original Article 06 June 2015 Pages: 269 - 277
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer Shinya UedaHisato KawakamiKazuhiko Nakagawa Original Article 07 June 2015 Pages: 279 - 285
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4–p53 interaction Susan M. ChristnerDana M. ClausenJulie L. Eiseman Original Article 07 June 2015 Pages: 287 - 299
Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist Taisuke EzakiTakeo KosakaMototsugu Oya Original Article 09 June 2015 Pages: 301 - 306
Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway Hongyan WuFangtian FanYin Lu Original Article 11 June 2015 Pages: 307 - 315
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer Rory J. MakielskiSam J. LubnerNoelle K. LoConte Original Article 12 June 2015 Pages: 317 - 323
Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse Fumiaki YamashitaIkumi KomotoMasato Chiba Original Article 18 June 2015 Pages: 325 - 333
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study Shoji NagaoShin NishioJunzo Kigawa Original Article 20 June 2015 Pages: 335 - 342
Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363 James W. T. YatesPhillippa DudleyBarry R. Davies Original Article 20 June 2015 Pages: 343 - 356
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis Motoo NomuraIsao OzeManabu Muto Original Article 20 June 2015 Pages: 357 - 363
Population pharmacokinetics of kahalalide F in advanced cancer patients Bernardo Miguel-LilloBelén ValenzuelaJuan José Pérez-Ruixo Original Article 21 June 2015 Pages: 365 - 374
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy Yasuhiro MitsuiYasushi SatoTetsuji Takayama Original Article 23 June 2015 Pages: 375 - 382
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells Johannes KrausMarianne KrausChristoph Driessen Original Article Open access 23 June 2015 Pages: 383 - 396
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer Clarinda ChuaIain Beehuat TanSu-Pin Choo Original Article 24 June 2015 Pages: 397 - 408
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors Toshihiko DoiKenji TamuraAtsushi Ohtsu Original Article Open access 24 June 2015 Pages: 409 - 416
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer Ursula MatulonisSuzanne BerlinNeil Horowitz Original Article 29 June 2015 Pages: 417 - 423
Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma Pascal ChastagnerBénédicte DevictorNicolas André Clinical Trial Report 27 June 2015 Pages: 425 - 432
Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib? Letizia PorcelliGabriella GuidaAmalia Azzariti Short Communication 13 June 2015 Pages: 433 - 438